Table 3.
Characteristics of the nine patients with multi-drug resistant Acinetobacter baumannii isolation
| No. | Source | Concurrent bacteremia | APACHE II score | TBSA (%) | LOS before MDRAB occurrence | Days from MDRAB occurrence to clearance | Antimicrobial use before MDRAB isolation | Antimicrobial use after MDRAB isolation |
|---|---|---|---|---|---|---|---|---|
| 1 | Wound | no | 6 | 40 | 16 | 10 | Teicoplanin, imipenem | Teicoplanin, ceftazidime |
| 2 | Wound | no | 4 | 60 | 15 | 14 | Teicoplanin, imipenem | Teicoplanin, ceftazidime |
| 3 | Wound | no | 7 | 40 | 22 | 9 | Teicoplanin, imipenem | Teicoplanin, meropenem |
| 4 | CVC | no | 4 | 35 | 11 | NA | Teicoplanin, ceftazidime | Teicoplanin, ceftazidime |
| 5 | Wound |
Klebsiella pneumoniae
Staphylococcus haemolyticus |
9 | 55 | 11 | 21 | Teicoplanin, imipenem | Daptomycin, imipenem |
| 6 | Wound | no | 6 | 60 | 26 | 10 | Teicoplanin, ceftazidime | Cefepime |
| 7 | Wound |
Acinetobacter pittii
Staphylococcus haemolyticus |
13 | 80 | 16 | 14 | Teicoplanin, imipenem | Teicoplanin + impenem + colistin, teicoplanin + cefaperazone/sulbactam |
| 8 | Wound | no | 6 | 50 | 18 | 10 | Teicoplanin, imipenem | Teicoplanin + ceftazidime |
| 9 | Wound | no | 4 | 40 | 6 | 10 | Teicoplanin, ceftazidime | Teicoplanin + cefaperazone/sulbactam |
MDRAB was cleared before discharge for all the patients except one person (No. 4) who had a removed central venous catheter (CVC) with MDRAB detection. All the cases survived and were discharged from the hospital uneventfully
CVC central venous catheter, LOS length of stay, MDRAB multi-drug resistant Acinetobacter baumannii, NA not applicable, TBSA total body surface area